Status:
UNKNOWN
Value of Cardiac Rehabilitation on the Treatment of Cardiovascular Disease
Lead Sponsor:
Shenzhen People's Hospital
Conditions:
Cardiac Rehabilitation
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease. Current guidelines support its use in patients after acute coronary syndrome, coronary artery bypa...
Detailed Description
The trial was conducted in Shenzhen in China. This study will recruit 100 patients with cardiovascular disease with a median and minimum follow-up of 24 and 6 months. Patients will be individually ran...
Eligibility Criteria
Inclusion
- Cardiovascular disease
Exclusion
- Incalculable TFC
- Coronary artery spasm or ectasia
- LV ejection fraction \< 52% in males or \< 54% in females
- Abnormal heart structure (congenital heart disease, cardiomyopathies, or valvular dysfunction)
- Pericardial disease (pericardial effusion or constrictive pericarditis)
- Previous history of myocardial infarction
- Uncontrolled hypertension (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 105 mmHg)
- Hyperthyroidism
- Hypothyroidism
- Malignancy
- Autoimmune disease
- Infection
- Pulmonary, hepatic, and renal disorders
- Haematological disorders (anaemia, bone marrow involved by neoplastic disease, or red blood cell transfusions)
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05320848
Start Date
February 1 2021
End Date
February 1 2025
Last Update
April 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen People's Hospital
Shenzhen, China